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Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging public health problem worldwide.
Severe invasive infections have been described, mostly associated with the presence of Panton-Valentine leukocidin (PVL). In
Portugal limited information exists regarding CA-MRSA infections. In this study we describe the case of a previously healthy 12-
year-old female, sport athlete, who presented to the hospital with acetabulofemoral septic arthritis, myositis, fasciitis, acetabulum
osteomyelitis, and pneumonia.TheMRSA isolated from blood and synovial fluid was PVL negative and staphylococcal enterotoxin
type P (SEP) and type L (SEL) positive, with a vancomycin MIC of 1.0mg/L and resistant to clindamycin and ciprofloxacin. The
patient was submitted to multiple surgical drainages and started on vancomycin, rifampicin, and gentamycin. Due to persistence of
fever and no microbiological clearance, linezolid was started with improvement. This is one of the few reported cases of severe
invasive infection caused byCA-MRSA inPortugal, whichwas successfully treatedwith linezolid. In spite of the severity of infection,
the MRSA isolate did not produce PVL.
1. Introduction
Staphylococcus aureus is a common cause of disease in chil-
dren. Although the overall prevalence of community-asso-
ciated methicillin-resistant S. aureus (CA-MRSA) is variable,
it is increasing worldwide, particularly in the United States
(reaching 70% in Texas) and Australia [1, 2]. In Portugal
although a study by Tavares et al. [3] showed that the pro-
portion of MRSA among colonizing S. aureus isolates in Por-
tuguese children was less than 1%, recent studies performed
among patients with no risk factors for previous hospital
contact, screened at hospital entrance, showed that MRSA
frequency in infection, in the community, in Portugal, may
be much higher, around 25% (Tavares et al., unpublished).
CA-MRSA usually differ in several ways from typical
health-care-associated MRSA (HA-MRSA). They typically
carry the smallest staphylococcal cassette chromosome mec
(SCCmec) types IV and V, are resistant to fewer antimicrobial
agents, and are associated to the presence and enhanced
expression of specific virulence factors [4, 5]. Indeed, Panton-
Valentine Leukocidin (PVL) has been associated with severe
and complicated CA-MRSA osteoarticular infections [6–8].
In 2005, Gonzalez et al. reported 14 adolescents present-
ing severe S. aureus sepsis [9].These patients were considered
unusual because of their illness severity, as well as the notice-
able absence of underlyingmedical conditions or risk factors.
All isolated strainswere identical or closely related toUSA300
and 12 were MRSA. In recent years several groups reported
other invasive, severe, MRSA infections, such as multifocal
osteomyelitis, pyomyositis, or necrotizing pneumonia [9–11].
Data on these invasive infections is scarce in Portugal. In
addition, although there are several published guidelines,
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Figure 1: Bilateral pneumonia with effusion.
the management of these infections is still not consensual
[12, 13]. Our aim is to report an adolescent with a severe, life-
threatening infection by amultiresistant PVL negativeMRSA
acquired in the community whose treatment was difficult, but
successful.
2. Case Presentation
A previously healthy 12-year-old female, sport athlete, with
eczema, presented to the hospital with fever and right hip
pain. She described a nontraumatic, progressive, nonradiat-
ing pain on the right groin. She was treated with ibuprofen
for pain. Reevaluation one week later demonstrated deeper
pain with erythema and swelling on the right hip/groin.
She denied previous infections or recent hospitalization.
Laboratory findings included leukocytosis (15 × 103/mm3)
and high C-reactive protein (29.5mg/dL). Right hip echog-
raphy revealed arthritis with effusion.The diagnosis of septic
arthritis was made and the patient was admitted at another
hospital, submitted hip arthrocentesis, and started on intra-
venous flucloxacillin. Blood and joint fluid cultures obtained
upon admission grew MRSA, with a MIC for vancomycin of
1.0mg/L, also resistant to clindamycin (cMLSB) and cipro-
floxacin. Her antimicrobial therapy was then changed to IV
vancomycin and gentamycin.
At day 7 after admission, despite adequate antibiotic ther-
apy and drainage, clinical deterioration was evident and she
was transferred to our unit. On physical examination, she was
toxic appearing, with respiratory distress and hypoxemia.The
pulmonary examination revealed crackles and a decreased
right vesicularmurmur.Her right groin and thighwerewarm,
swollen, and intensely tender and there was a diffuse rash on
both legs.
On laboratory evaluation anemia, leucocytosis (total
14.4 × 10
3/mm3, neutrophils 67.5%), high C-reactive protein
(32mg/dL), and hyponatremia, with abnormal coagulation
profile was noted. Chest radiography demonstrated bilateral
pleural effusion and right pneumonia (Figure 1). Magnetic
resonance image (MRI) showed hip septic arthritis, myosi-
tis, fasciitis, acetabulum osteomyelitis, and femoral head
osteonecrosis (Figure 2). A transthoracic echocardiogram
did not show vegetation. Deep venous thrombosis was
excluded.
The MRSA strain was characterized by spa typing [14],
multilocus sequence typing (MLST) [15], SCCmec typing
(a)
(b)
Figure 2: Axial T2-weighted (a) image, with fat saturation, showing
right hip effusion and extensive myositis. A four weeks later (b)
coronal T1 image with fat saturation, after gadolinium, showing
increased signal intensity in the right femoral head, with erosions.
There was associated edema of the surrounding tissues, hip effusion
and myositis with abscess.
[16, 17] and checked for the presence of PVL [18] and spe-
cific staphylococcal virulence determinants, including leuko-
cidins, hemolysins, superantigenic toxins, and the arginine
catabolic mobile genetic element (ACME) [4, 19, 20]. The
MRSA isolate belonged to the ST22-IVnt-t1214 and did not
carry PVL. The isolate was Staphylococcal enterotoxin type
P (SEP) and type L (SEL) positive but negative for gama-
hemolysin, alfa-hemolysin, ETA, ETB, or ACME and had a
vancomycin MIC of 1𝜇g/mL. The clonal type found asso-
ciated to this isolate is related to the most common clonal
types in Portuguese hospitals nowadays, the EMRSA-15
clone. The exact clonal type identified in this work (ST22-
IVnt-t1214) had not been described before in Portugal. The
differences to the most common nosocomial clonal type
found in this country (ST22-IVh-t032) correspond to the
subtype of SCCmec IV, that in this isolate was non-typeable,
and the deletion of two repeats in the spa gene (t1214: 26-
23-23-13-23-31-29-17-31-29-17-25-16-28/t032: 26-23-23-13-23-
31-29-17-31-29-17-25-17-25-16-28).
The patient was submitted to multiple arthrocentesis,
muscular drainage, and also to thoracentesis. The patient
required mechanical ventilation and was transferred to
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the PICU. The vancomycin dose was adjusted targeting a
trough concentration of 15 𝜇g/mL and rifampicin was added
to the antimicrobial regimen. Given the clinical severity IV
immunoglobulin 2 g/Kg was administered.
At day 22 after admission (17th day of sensitive antimicro-
bial therapy) she maintained fever and severe pain at mobi-
lization of the right hip. Articular effusion cultures were still
positive for MRSA and multiple pyomyositis focus was yet
present onMRI.The antimicrobial therapy was then changed
to linezolid (10mg/kg/dose every 8 h) keeping gentamycin
and rifampicin.
The patient demonstrated gradual improvement of symp-
toms with apyrexia and pain improvement. The patient was
discharged home 48 days after hospital admission on oral
linezolid and rifampicin. Linezolid was maintained for 4
months with gradual improvement. Althoughmoderate neu-
tropenia (1000/𝜇L) was noted two months after starting line-
zolid, the drug was not discontinued with reversal. No other
secondary effects were noted. Follow-up at one year showed
mild functional disability.
3. Discussion
CA-MRSA is becoming more prevalent in Europe and prob-
ably is an emergent pathogen in Portugal as well, although
limited information exists regarding CA-MRSA infections
prevalence in the country. In a recent study from Portuguese
children with mild skin and soft tissue infections attending
a pediatric emergency department, Conceic¸a˜o et al. [21],
observed that 10% of all S. aureus isolated were MRSA, but
more recent studies indicate that this rate is higher (Tavares et
al., unpublished). To the best of our knowledge only a single
case of severe infection was previously reported in Portugal
that is of a young adult with severe necrotizing pneumonia,
complicated with bilateral empyema and respiratory failure
[22].
In the United States, life-threatening S. aureus infections
have been described more frequently among healthy ado-
lescents, usually related to a specific virulent strain (USA
300) [9]. Kaplan et al. described that MRSA osteoarticular
infections were more frequently multifocal and had a slower
clinical cure thanMSSA infections [1]. AlsoMart´ınez-Aguilar
et al. comparing MSSA and MRSA pediatric osteomyelitis
reported that the number of hospital and febrile days was
significantly higher in the MRSA group [6]. Bocchini et al.
attributed most of these differences to the production of
PVL [23]. Also, myositis and pyomyositis are being recog-
nized with increasing frequency in children with CA-MRSA
infections, and multiple sites of muscle involvement with
concomitant osteomyelitis are not unusual [24, 25]. Certainly,
our adolescent MRSA osteomyelitis, although PVL-negative,
was severe, extended, and multifocal, is associated to necro-
tizing fasciitis, osteonecrosis, and pyomyositis. Multiple drai-
nages, PICU support, and prolonged hospitalization were
required. In this case, probably other virulent factors besides
PVL, such as SEL and SEP, might be implicated. In fact,
staphylococcal superantigens are potent activators of the
immune system, namely, of antigen-presenting cells and T
lymphocytes, which leads to the excessive production of pro-
inflammatory cytokines and T-cell proliferation and could
have been the cause of the shock, fever, and finally the septic
arthritis observed [26]. Actually, it was demonstrated in vivo
that, in staphylococci, superantigens are important virulence
factors in the development of septic arthritis [27].
Treatment of severe CA-MRSA requires aggressive med-
ical and surgical intervention, with long course of antibi-
otics, drainage, and thorough debridement [12]. Various
antimicrobial regimens have been proposed [12, 13, 28, 29].
The BSAC guidelines suggest, for CA-MRSA osteomyelitis
and other deep-seated infections, initial treatment with
parental vancomycin, teicoplanin, daptomycin, or linezolid
[13]. Also, the IDSA guidelines for children advise parenteral
vancomycin for first-line therapy. Alternative options are
linezolid or clindamycin [12].
In recent years, however, vancomycin efficacy has been
quizzed [12]. Vancomycin is not as effective as oxacillin/
nafcillin for bacteremic pulmonary MSSA infections [30].
Also, failure rates of up to 35%–46% and a higher recurrence
rate have been reported for MRSA osteomyelitis treated
with vancomycin [31, 32]. Its slow bactericidal activity,
the possible “MIC creep” among susceptible strains, and
low concentrations achieved at the site of infection have
been implicated [33]. These unsatisfactory responses to van-
comycin have led some experts to recommend the addition of
rifampin or protein synthesis inhibitors in severe infections
[32]. Moreover for necrotizing fasciitis, necrotizing pneumo-
nia, and toxic shock, there could be a theoretical advantage
for using two or three agents such as linezolid combined with
clindamycin and rifampicin [13]. Rifampicin could be added
based on excellent tissue penetration, synergistic activity, and
intracellular clearing of Staphylococcus [13].
Given the severity of our adolescent infection and the
pattern of MRSA resistance (resistant to clindamycin and
levofloxacin), gentamycin and rifampicin were added to
vancomycin. However, after two weeks of combined therapy,
and even with a MIC for vancomycin inferior to 1.5 𝜇g/mL
and a trough concentration of 15𝜇g/mL, there was no clinical
improvement and linezolid was started.
Linezolid, an oxazolidinone antibiotic, is FDA-approved
for adults and children for the treatment of skin/soft tissue
infections and pneumonia due to MRSA [34]. Nervous sys-
tem and osteoarticular infections are off-label indications.
It seems equivalent or superior to vancomycin for bactere-
mic infections [35]. However, clinical experience with pro-
longed linezolid use in children is limited [36, 37]. The
most common adverse reactions are nausea, vomiting, and
diarrhea. Mild and reversible myelosuppression has been
reported in children [38]. Peripheral and optic neuropathy
may also occur with prolonged administration and are only
partially reversible. In our patient, the clinical response to
linezolid was excellent with apyrexia and gradual improve-
ment of inflammatory parameters. Although leukopenia was
noted, and monitored weekly, it was reversible and had
no implications on treatment duration. Though intravenous
immunoglobulin is not routinely recommended as adjunctive
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therapy for themanagement of invasiveMRSA disease, it was
used with good initial response [12].
The MRSA isolate collected belonged to the ST22-IVnt-
t1214, clonal type, which is related to themost frequentMRSA
clonal type in Portuguese hospitals nowadays—the EMRSA-
15 clone. Although this is a hospital-associated clone, the
EMRSA-15 was previously collected from infections in the
community worldwide and also in Portugal (Espadinha et al.
and Tavares et al., unpublished) and carries genetic char-
acteristics that are present in CA-MRSA clones: carriage of
SCCmec IV and few antimicrobial resistance determinants.
These results suggest that the MRSA strain causing the
invasive infection reported in this study might have had a
hospital origin. However, it is also plausible that the MRSA
isolate was once originated in the hospital and survived in the
community environment long enough to be isolated from a
person with no previous hospital contact.
To our knowledge this is one of the few reported cases
of severe invasive infection caused by CA-MRSA successfully
treated with linezolid in our country.The severity of infection
was not due to the production of PVL, butmight be associated
with the presence of superantigens SEL and SEP.
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